Literature DB >> 21052776

Radiographic patterns of relapse in glioblastoma.

Marc C Chamberlain1.   

Abstract

Glioblastoma (GBM) pathologically is defined as an infiltrative glioma and salvage therapy with bevacizumab is believed to increase the incidence of diffuse and distant invasion as assessed radiographically. Eighty adult patients with glioblastoma were treated with surgery followed by radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ). At first recurrence, 80 patients were treated with single agent bevacizumab. At time of progression, 57 patients were treated with bevacizumab and a cytotoxic chemotherapy, cytotoxic chemotherapy alone or on an investigational trial. Magnetic resonance imaging (MRI) were analyzed at four time points in each patient; at presentation, at first, second and third recurrence. Four patterns of radiographic disease were assessed, local (unifocal disease), distant (second lesion noncontiguous with primary lesion), multifocal (>2 lesions including leptomeningeal dissemination) and diffuse. At presentation 87.5% of glioblastoma were local, 6.25% distant, 3.75% multifocal and 2.5% diffuse. At first recurrence following progression on RT/TMZ and before initiation of bevacizumab, 80% were local, 7.5% distant, 6.25% multifocal (including 1 with CSF dissemination) and 6.25% diffuse. At second recurrence following progression on bevacizumab, 71.25% were local, 8.75% distant, 8.75% multifocal (2/7 with CSF dissemination) and 11.25% were diffuse. At third recurrence (57 patients evaluable), 71.25% were local, 7.0% distant, 7.0% multifocal and 14.0% were diffuse. Survival following progression on bevacizumab did not differ by pattern of radiographic recurrence. A majority of adult patients with GBM at diagnosis manifest MRI-defined local disease and maintain this pattern notwithstanding multiple recurrences and treatment with bevacizumab.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052776     DOI: 10.1007/s11060-010-0251-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 3.  The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults.

Authors:  D L Silbergeld; R C Rostomily; E C Alvord
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

4.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Authors:  F M Iwamoto; L E Abrey; K Beal; P H Gutin; M K Rosenblum; V E Reuter; L M DeAngelis; A B Lassman
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

5.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

6.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

7.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

8.  Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

Authors:  Eudocia C Quant; Andrew D Norden; Jan Drappatz; Alona Muzikansky; Lisa Doherty; Debra Lafrankie; Abigail Ciampa; Santosh Kesari; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2009-03-30       Impact factor: 12.300

9.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Authors:  Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-23       Impact factor: 7.038

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

  10 in total
  73 in total

Review 1.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

2.  Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations.

Authors:  A Ruth He; Alec S Goldenberg
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

3.  Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Authors:  Benjamin M Ellingson; Albert Lai; Huytram N Nguyen; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2015-04-21       Impact factor: 12.531

Review 4.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

5.  LIM domain only 2 induces glioma invasion via cytosolic p27(KIP1).

Authors:  Cheol Gyu Park; Young-Woo Sohn; Eun-Jung Kim; Sung-Hak Kim; Sung-Chan Kim; Hyunggee Kim
Journal:  Tumour Biol       Date:  2015-09-18

6.  Comparative Analysis of Subventricular Zone Glioblastoma Contact and Ventricular Entry During Resection in Predicting Dissemination, Hydrocephalus, and Survival.

Authors:  Akshitkumar M Mistry; Patrick D Kelly; Jean-Nicolas Gallant; Nishit Mummareddy; Bret C Mobley; Reid C Thompson; Lola B Chambless
Journal:  Neurosurgery       Date:  2019-11-01       Impact factor: 4.654

7.  Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.

Authors:  L R Kleinberg; V Stieber; T Mikkelsen; K Judy; J Weingart; G Barnett; J Olson; S Desideri; X Ye; S Grossman
Journal:  J Radiat Oncol       Date:  2015-08-05

8.  Malignancy probability map as a novel imaging biomarker to predict malignancy distribution: employing MRS in GBM patients.

Authors:  Manijeh Beigi; Kevan Ghasemi; Parvin Mirzaghavami; Mohammadreza Khanmohammadi; Hamidreza SalighehRad
Journal:  J Neurooncol       Date:  2018-03-14       Impact factor: 4.130

Review 9.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

Review 10.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.